* participation in other investigational clinical trials for the treatment or prevention of sars-cov-2 infection within 30days. * subjects unwilling to practice at least one highly effective method of birth control for the duration of the study. * having a prior history of blood disorders such as aplastic anemia, agranulocytosis, leukopenia, or thrombocytopenia or prior history of glucose-6-phosphate dehydrogenase (g-6-pd) deficiency. * having h/o skin disorders e.g. dermatitis, psoriasis or porphyria. * taking any of the following medication: * anti-arrythmic agents including digoxin. * gi drugs including antacids, proton-pump inhibitors, cimetidine. * anti-cancer treatment including methotrexate, cyclosporin. * anti-diabetic agents including insulin. * corticosteroids. * drugs causing qt interval prolongation especially antidepressants, anti-epileptics and macrolides. * drugs affecting electrolyte balance including diuretics, laxatives. * drug allergies: 4-aminoquinolines. * pre-existing retinopathy/maculopathy of the eye. * known chronic liver disease or cirrhosis, including hepatitis b and/or untreated hepatitis. * previous history of severe hypoglycaemia. * known case of renal disease. * untreated or uncontrolled active bacterial, fungal infection. * known or suspected active drug or alcohol abuse. * women who are pregnant or breastfeeding. * known hypersensitivity to any component of the study drug. * a known history of prolonged qt syndrome or history of additional risk factors for arrythmias (e.g., heart failure, family history of long qt syndrome). * known h/o respiratory disorders e.g. asthma, chronic obstructive pulmonary disease.

* participation in other investigational clinical trials for the treatment or prevention of sars-cov-2 infection within 30days. * subjects unwilling to practice at least one highly effective method of birth control for the duration of the study. * having a prior history of blood disorders such as aplastic anemia, agranulocytosis, leukopenia, or thrombocytopenia or prior history of glucose-6-phosphate dehydrogenase (g-6-pd) deficiency. * having h/o skin disorders e.g. dermatitis, psoriasis or porphyria. * taking any of the following medication: * anti-arrythmic agents including digoxin. * gi drugs including antacids, proton-pump inhibitors, cimetidine. * anti-cancer treatment including methotrexate, cyclosporin. * anti-diabetic agents including insulin. * corticosteroids. * drugs causing qt interval prolongation especially antidepressants, anti-epileptics and macrolides. * drugs affecting electrolyte balance including diuretics, laxatives. * drug allergies: 4-aminoquinolines. * pre-existing retinopathy/maculopathy of the eye. * known chronic liver disease or cirrhosis, including hepatitis b and/or untreated hepatitis. * previous history of severe hypoglycaemia. * known case of renal disease. * untreated or uncontrolled active bacterial, fungal infection. * known or suspected active drug or alcohol abuse. * women who are pregnant or breastfeeding. * known hypersensitivity to any component of the study drug. * a known history of prolonged qt syndrome or history of additional risk factors for arrythmias (e.g., heart failure, family history of long qt syndrome). * known h/o respiratory disorders e.g. asthma, chronic obstructive pulmonary disease.

- participation in other investigational clinical trials for the treatment or prevention of sars-cov-2 infection within 30days. - subjects unwilling to practice at least one highly effective method of birth control for the duration of the study. - having a prior history of blood disorders such as aplastic anemia, agranulocytosis, leukopenia, or thrombocytopenia or prior history of glucose-6-phosphate dehydrogenase (g-6-pd) deficiency. - having h/o skin disorders e.g. dermatitis, psoriasis or porphyria. - taking any of the following medication: - anti-arrythmic agents including digoxin. - gi drugs including antacids, proton-pump inhibitors, cimetidine. - anti-cancer treatment including methotrexate, cyclosporin. - anti-diabetic agents including insulin. - corticosteroids. - drugs causing qt interval prolongation especially antidepressants, anti-epileptics and macrolides. - drugs affecting electrolyte balance including diuretics, laxatives. - drug allergies: 4-aminoquinolines. - pre-existing retinopathy/maculopathy of the eye. - known chronic liver disease or cirrhosis, including hepatitis b and/or untreated hepatitis. - previous history of severe hypoglycaemia. - known case of renal disease. - untreated or uncontrolled active bacterial, fungal infection. - known or suspected active drug or alcohol abuse. - women who are pregnant or breastfeeding. - known hypersensitivity to any component of the study drug. - a known history of prolonged qt syndrome or history of additional risk factors for arrythmias (e.g., heart failure, family history of long qt syndrome). - known h/o respiratory disorders e.g. asthma, chronic obstructive pulmonary disease.

- participation in other investigational clinical trials for the treatment or prevention of sars-cov-2 infection within 30days. - subjects unwilling to practice at least one highly effective method of birth control for the duration of the study. - having a prior history of blood disorders such as aplastic anemia, agranulocytosis, leukopenia, or thrombocytopenia or prior history of glucose-6-phosphate dehydrogenase (g-6-pd) deficiency. - having h/o skin disorders e.g. dermatitis, psoriasis or porphyria. - taking any of the following medication: - anti-arrythmic agents including digoxin. - gi drugs including antacids, proton-pump inhibitors, cimetidine. - anti-cancer treatment including methotrexate, cyclosporin. - anti-diabetic agents including insulin. - corticosteroids. - drugs causing qt interval prolongation especially antidepressants, anti-epileptics and macrolides. - drugs affecting electrolyte balance including diuretics, laxatives. - drug allergies: 4-aminoquinolines. - pre-existing retinopathy/maculopathy of the eye. - known chronic liver disease or cirrhosis, including hepatitis b and/or untreated hepatitis. - previous history of severe hypoglycaemia. - known case of renal disease. - untreated or uncontrolled active bacterial, fungal infection. - known or suspected active drug or alcohol abuse. - women who are pregnant or breastfeeding. - known hypersensitivity to any component of the study drug. - a known history of prolonged qt syndrome or history of additional risk factors for arrythmias (e.g., heart failure, family history of long qt syndrome). - known h/o respiratory disorders e.g. asthma, chronic obstructive pulmonary disease.